BIOMARKER FOR MONITORING PATIENTS

BIOMARKER FOR MONITORING PATIENTS

Provided is an ex-vivo method for assessing the efficacy of a treatment in a patient receiving an immunogenic composition, wherein the method comprises: measuring levels of interferon gamma in a biological sample from the patient after the patient has received the immunogenic composition; wherein le...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BERANGERE, MARIE-BASTIEN, ACRES, BRUCE
Format: Patent
Sprache:eng
Schlagworte:
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
PHYSICS
TESTING
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator BERANGERE, MARIE-BASTIEN
ACRES, BRUCE
description Provided is an ex-vivo method for assessing the efficacy of a treatment in a patient receiving an immunogenic composition, wherein the method comprises: measuring levels of interferon gamma in a biological sample from the patient after the patient has received the immunogenic composition; wherein levels of interferon gamma above about 4 pg/ml indicate a successful clinical outcome for the treatment and wherein said immunogenic composition contains at least one recombinant viral vector expressing in vivo all or part of MUC antigen, provided that the recombinant viral vector does not express interferon gamma.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_NZ595290A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NZ595290A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_NZ595290A3</originalsourceid><addsrcrecordid>eNrjZFB08vT3dQzydg1ScPMPUvD19_MM8Q_y9HNXCHAM8XT1CwnmYWBNS8wpTuWF0twMcm6uIc4euqkF-fGpxQWJyal5qSXxflGmlqZGlgaOxgQVAABr6CFd</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>BIOMARKER FOR MONITORING PATIENTS</title><source>esp@cenet</source><creator>BERANGERE, MARIE-BASTIEN ; ACRES, BRUCE</creator><creatorcontrib>BERANGERE, MARIE-BASTIEN ; ACRES, BRUCE</creatorcontrib><description>Provided is an ex-vivo method for assessing the efficacy of a treatment in a patient receiving an immunogenic composition, wherein the method comprises: measuring levels of interferon gamma in a biological sample from the patient after the patient has received the immunogenic composition; wherein levels of interferon gamma above about 4 pg/ml indicate a successful clinical outcome for the treatment and wherein said immunogenic composition contains at least one recombinant viral vector expressing in vivo all or part of MUC antigen, provided that the recombinant viral vector does not express interferon gamma.</description><language>eng</language><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; PHYSICS ; TESTING</subject><creationdate>2012</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20120928&amp;DB=EPODOC&amp;CC=NZ&amp;NR=595290A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20120928&amp;DB=EPODOC&amp;CC=NZ&amp;NR=595290A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BERANGERE, MARIE-BASTIEN</creatorcontrib><creatorcontrib>ACRES, BRUCE</creatorcontrib><title>BIOMARKER FOR MONITORING PATIENTS</title><description>Provided is an ex-vivo method for assessing the efficacy of a treatment in a patient receiving an immunogenic composition, wherein the method comprises: measuring levels of interferon gamma in a biological sample from the patient after the patient has received the immunogenic composition; wherein levels of interferon gamma above about 4 pg/ml indicate a successful clinical outcome for the treatment and wherein said immunogenic composition contains at least one recombinant viral vector expressing in vivo all or part of MUC antigen, provided that the recombinant viral vector does not express interferon gamma.</description><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>PHYSICS</subject><subject>TESTING</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2012</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFB08vT3dQzydg1ScPMPUvD19_MM8Q_y9HNXCHAM8XT1CwnmYWBNS8wpTuWF0twMcm6uIc4euqkF-fGpxQWJyal5qSXxflGmlqZGlgaOxgQVAABr6CFd</recordid><startdate>20120928</startdate><enddate>20120928</enddate><creator>BERANGERE, MARIE-BASTIEN</creator><creator>ACRES, BRUCE</creator><scope>EVB</scope></search><sort><creationdate>20120928</creationdate><title>BIOMARKER FOR MONITORING PATIENTS</title><author>BERANGERE, MARIE-BASTIEN ; ACRES, BRUCE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_NZ595290A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2012</creationdate><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>PHYSICS</topic><topic>TESTING</topic><toplevel>online_resources</toplevel><creatorcontrib>BERANGERE, MARIE-BASTIEN</creatorcontrib><creatorcontrib>ACRES, BRUCE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BERANGERE, MARIE-BASTIEN</au><au>ACRES, BRUCE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>BIOMARKER FOR MONITORING PATIENTS</title><date>2012-09-28</date><risdate>2012</risdate><abstract>Provided is an ex-vivo method for assessing the efficacy of a treatment in a patient receiving an immunogenic composition, wherein the method comprises: measuring levels of interferon gamma in a biological sample from the patient after the patient has received the immunogenic composition; wherein levels of interferon gamma above about 4 pg/ml indicate a successful clinical outcome for the treatment and wherein said immunogenic composition contains at least one recombinant viral vector expressing in vivo all or part of MUC antigen, provided that the recombinant viral vector does not express interferon gamma.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_NZ595290A
source esp@cenet
subjects INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
PHYSICS
TESTING
title BIOMARKER FOR MONITORING PATIENTS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T01%3A45%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BERANGERE,%20MARIE-BASTIEN&rft.date=2012-09-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ENZ595290A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true